AbbVie Sues HRSA in D.C. District Court Over 340B Patient Definition — Post-Chevron Doctrinal Weapon

AbbVie filed a 72-page complaint April 8 in U.S. District Court for the District of Columbia against HRSA, HHS, Secretary Kennedy, and HRSA Administrator Engels — targeting the 1996 'patient definition' guidance that allows 340B drugs to be dispensed to non-FQHC contract patients. Post-Chevron doctrinal weapon: AbbVie argues HRSA's interpretive guidance lacks force of law. If successful, would dramatically narrow which patients qualify for 340B savings and gut FQHC contract pharmacy revenue. Joins the pending Maine District Court case (AHA + 4 safety-net hospitals, already vacated rebate model in Feb 2026). Combined regulatory + litigation pressure on HRSA's 340B authority is the most concentrated industry challenge in program history.